LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Search

Cytek Biosciences Inc

Suletud

SektorTervishoid

4.24 1.92

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.17

Max

4.37

Põhinäitajad

By Trading Economics

Sissetulek

105K

-5.5M

Müük

6.7M

52M

Aktsiakasum

-0

Kasumimarginaal

-10.476

Töötajad

692

EBITDA

6.4M

-4.2M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+38.34% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

26. veebr 2026

Turustatistika

By TradingEconomics

Turukapital

69M

570M

Eelmine avamishind

2.32

Eelmine sulgemishind

4.24

Uudiste sentiment

By Acuity

17%

83%

22 / 352 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Cytek Biosciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

12. veebr 2026, 23:57 UTC

Kuumad aktsiad

Stocks to Watch: Applied Materials, Arista, DraftKings, Pinterest

12. veebr 2026, 23:35 UTC

Tulu
Suurimad hinnamuutused turgudel

Arista Networks Surges on AI Networking Demand, Despite Rising Costs

12. veebr 2026, 23:28 UTC

Tulu

Applied Materials Profit Rises on Soaring AI Demand -- Update

12. veebr 2026, 21:47 UTC

Tulu

Vertex Pharmaceuticals Revenue Climbs on Continued Cystic Fibrosis Demand

13. veebr 2026, 00:00 UTC

Market Talk

ANZ Gets a New Bull as Productivity Prospects Improve -- Market Talk

12. veebr 2026, 23:47 UTC

Market Talk

Nikkei May Fall After AI Concerns Drag Stocks on Wall Street -- Market Talk

12. veebr 2026, 23:38 UTC

Market Talk

Gold Steady; Could Undergo Technical Recovery -- Market Talk

12. veebr 2026, 23:33 UTC

Tulu

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- 2nd Update

12. veebr 2026, 23:09 UTC

Market Talk

South32's Hermosa Review Stokes Spending Fears -- Market Talk

12. veebr 2026, 22:55 UTC

Tulu
Kuumad aktsiad

Applied Materials, DraftKings, Airbnb: Earnings in Focus -- WSJ

12. veebr 2026, 22:46 UTC

Market Talk

Northern Star Outlook Needs Project Done On Time, In Budget -- Market Talk

12. veebr 2026, 22:23 UTC

Tulu

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- Update

12. veebr 2026, 22:15 UTC

Tulu

Agnico-Eagle Mines: Gold Production for 2026 and 2027, Expected at 3.3M to 3.5M Ounces Annually, Is Consistent With Previous Guidance, With Offsetting Adjustments Between Mine Sites >AEM.T

12. veebr 2026, 22:15 UTC

Tulu

Agnico-Eagle Mines Raises Dividend to 45c >AEM.T

12. veebr 2026, 22:15 UTC

Tulu

Agnico-Eagle Mines 4Q Rev $3.56B >AEM.T

12. veebr 2026, 22:15 UTC

Tulu

Agnico-Eagle Mines 4Q EPS $3.04 >AEM.T

12. veebr 2026, 22:00 UTC

Tulu

AGNICO EAGLE REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS - RECORD QUARTERLY AND ANNUAL FREE CASH FLOW; 2025 PRODUCTION GUIDANCE ACHIEVED; TOTAL 2025 SHAREHOLDER RETURNS OF $1.4 BILLION; DIVIDEND INCREASED BY 12.5%; UPDATED THREE-YEAR GUIDANCE >AEM.T

12. veebr 2026, 22:00 UTC

Tulu

Agnico-Eagle Mines 4Q Rev $3.56B >AEM

12. veebr 2026, 22:00 UTC

Tulu

Agnico-Eagle Mines 4Q Net $1.52B >AEM

12. veebr 2026, 22:00 UTC

Tulu

Agnico-Eagle Mines 4Q Adj EPS $2.70 >AEM

12. veebr 2026, 22:00 UTC

Tulu

AGNICO EAGLE REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS - RECORD QUARTERLY AND ANNUAL FREE CASH FLOW; 2025 PRODUCTION GUIDANCE ACHIEVED; TOTAL 2025 SHAREHOLDER RETURNS OF $1.4 BILLION; DIVIDEND INCREASED BY 12.5%; UPDATED THREE-YEAR GUIDANCE >AEM.T

12. veebr 2026, 22:00 UTC

Tulu

Agnico-Eagle Mines 4Q EPS $3.04 >AEM

12. veebr 2026, 21:57 UTC

Tulu

XP 4Q Rev BRL4.95B >XP

12. veebr 2026, 21:52 UTC

Tulu

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

12. veebr 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

12. veebr 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

12. veebr 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12. veebr 2026, 21:47 UTC

Tulu

Morningstar 4Q Rev $641M >MORN

12. veebr 2026, 21:39 UTC

Tulu

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

12. veebr 2026, 21:38 UTC

Tulu

Howmet Stock Jumps. Earnings Show Strength For This Sector. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Cytek Biosciences Inc Prognoos

Hinnasiht

By TipRanks

38.34% tõus

12 kuu keskmine prognoos

Keskmine 6.17 USD  38.34%

Kõrge 7.5 USD

Madal 5 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Cytek Biosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

3 ratings

1

Osta

2

Hoia

0

Müü

Tehniline skoor

By Trading Central

3.7 / 3.8Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

22 / 352 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Keskmine

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Cytek Biosciences Inc

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
help-icon Live chat